A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes
F Javier Ampudia-Blasco, Pierre Yves Benhamou, Guillaume Charpentier, Agostino Consoli, Michaela Diamant, Baptist Gallwitz, Kamlesh Khunti, Chantal Mathieu, Martin Ridderstrale, Jochen Seufert, Cees Tack, Tina Vilsboll, Phan Tra-Mi, Herman Stoevelaar
Diabetes Technology & Therapeutics | MARY ANN LIEBERT, INC | Published : 2015
BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of treatment strategies for 930 clinical scenarios, which were permutations..View full abstract
Awarded by Novo Nordisk Fonden
The panel study and development of the decision tool were funded by Novo Nordisk Health Care AG, Zurich, Switzerland, as were the services of the medical writer for editorial support. The authors wish to express their respectful memory of Prof. Michaela Diamant who passed away during the panel study on April 9, 2014. They also wish to thank Jessa Yperman from Ismar Healthcare (Lier, Belgium) for performing the literature review and Dr. Sylvie Picard (Dijon, France) for her valuable advice in finalizing the electronic tool. Thanks are given to Deborah Nock (Medical Write-Away, United Kingdom) for some editorial support.